DSIJ Mindshare

The company has a market cap of over 1,418.29 crore with a 5-year CAGR of 205 per cent. The shares of the company have a ROE of 71 per cent and a ROCE of 96 per cent. The company’s net sales increased by 1 per cent to Rs 510 crore and net profit skyrocketed 400 per cent in FY23 over FY22.  

Over FY20-22, the company's consolidated sales increased at a CAGR of 23 per cent, headed by the headed lighting segment, which increased at a CAGR of 24 per cent during the same period.    

Operating profit stood at Rs 146 crore, an impressive jump of 102.77per cent over FY22.

Meropenem, a vital antibiotic for life-threatening infections, contributes 40 per cent to total sales. Venus Remedies launched it successfully in major European markets, securing 120+ marketing authorizations in countries like UK, France, Germany, UAE, and Australia. European market size: USD 70.34 million.

The company has delivered returns of 51 per cent over the past 3 years and returns of 74 per cent over the past 5 years. Moreover, the company has a healthy dividend payout ratio of 61.4 per cent.